Searched for
INSULIN MARKET
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- Stop chasing 10,000 steps daily: US entrepreneur Karl Mehta shares 7 simple walking habits that may control blood sugar level, improve healthThe 10,000-step goal, a marketing tactic, is challenged by research suggesting significant health benefits occur with around 7,000 steps da...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Artificial sweeteners may alter gut health and metabolism across generations, new study suggestsNew research suggests artificial sweeteners like sucralose and stevia could alter gut bacteria and metabolism. These changes may persist ac...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brandNovo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They ...
- Biocon Biologics looks to trim $300 million debt in 1 yearBiocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in d...
- Weekly-once insulin jab may soon come to IndiaA new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who ...
- Biocon eyes $30b US insulin market via its biosimilarsWith the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...
- Biocon links with Mexico's PiSA to tap US insulin marketBiocon said it has entered into a co-development and commercialization alliance with PiSA of Mexico for recombinant human insulin aimed at ...
- Biocon to focus on regional allies for commercialisationBiocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...
- Pfizer in $200 million insulin deal with BioconBiocon received $200 million upfront from New York-based Pfizerwhich is re-entering the $14-billion global insulin market almost four years...
- Danish drug co Novo Nordisk to set up data centreNovo Nordisk, a speciality pharma company with global leadership in the diabetes care market, has decided to set up its global data managem...
- India fast emerging as data management hubNovo Nordisk, a speciality pharma company with global leadership in the diabetes care market, has decided to set up its global data managem...
Load More
